MDACC Study No:2013-0566 ( NCT No: NCT02006485)
Title:A Multi-center Phase I/Ib Study Evaluating the Efficacy and Safety of Ublituximab, a Third-Generation Anti-CD20 Monoclonal Antibody, in Combination with TGR-1202, a Novel PI3k Delta Inhibitor, and Ibrutinib in Patients with B-cell Malignancies
Principal Investigator:Jan A. Burger
Treatment Agent:TGR-1202; Ublituximab
Study Status:Open
Study Description:The goal of this clinical research study is to learn the highest tolerable dose
of the combination of ublituximab and TGR-1202 or the combination of
ublituximab, TGR-1202 and ibrutinib that can be given to patients with B-cell
lymphoma, CLL or SLL. The safety of this study drug combination will also be
Hide details for General InformationGeneral Information

Disease Group:Leukemia; Lymphoma
Phase of Study:Phase I
Treatment Agents:TGR-1202
Treatment Location:Both at MDACC & and Other Sites
Estimated Length of Stay in Houston:
Supported By:TG Therapeutics, Inc.
Return Visit:
Home Care:

Hide details for Study Contact InformationStudy Contact Information

Physician Name:Jan A. Burger
For Clinical Trial Enrollment:713-792-7543
For General Questions about Clinical Trials:1-877-MDA-6789

Show details for Study Objectives / OutcomesStudy Objectives / Outcomes
Show details for Study Status InformationStudy Status Information
Show details for Enrollment EligibilityEnrollment Eligibility
Show details for Resources and LinksResources and Links
Show details for ResultsResults